|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
In-vivo Bioequivalence Study of Palbociclib 125 mg Hard Capsules of The Test Drug (PALBRANCE®, Arena Hayat Danesh, Iran) in Compared with The Reference Drug (IBRANCE® 125 mg, Pfizer Inc. Ireland) In Iranian Healthy Volunteers
A randomized, double-blind , parallel groups, multi center, non-inferiority and phase III clinical trial to compare the Efficacy and Safety of Altelyse (bio-similar Alteplase) versus the brand Actilyse in Acute MI patients with ST elevation
Pharmacokinetic evaluation and formulation of Ranolazine tablets in comparison with brand drug (RANEXA).
100 Clinical Results associated with Arena Life Science
0 Patents (Medical) associated with Arena Life Science
100 Deals associated with Arena Life Science
100 Translational Medicine associated with Arena Life Science